Needham & Company LLC Lowers Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target to $30.00

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its target price decreased by analysts at Needham & Company LLC from $34.00 to $30.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price objective suggests a potential upside of 48.29% from the company’s previous close.

A number of other brokerages have also issued reports on AMPH. Weiss Ratings reiterated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 29th. Barclays assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 price target for the company. Finally, Zacks Research lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 14th. Two research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $29.50.

Amphastar Pharmaceuticals Stock Down 23.6%

Shares of AMPH opened at $20.23 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.21 and a current ratio of 3.12. Amphastar Pharmaceuticals has a 52 week low of $19.83 and a 52 week high of $31.26. The stock has a market capitalization of $929.57 million, a price-to-earnings ratio of 9.97, a PEG ratio of 3.69 and a beta of 0.88. The stock has a fifty day moving average of $27.23 and a 200-day moving average of $26.99.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.73 earnings per share for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.24). The firm had revenue of $183.11 million for the quarter, compared to the consensus estimate of $190.48 million. Amphastar Pharmaceuticals had a return on equity of 17.74% and a net margin of 13.63%. As a group, sell-side analysts anticipate that Amphastar Pharmaceuticals will post 3.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 9,787 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $26.20, for a total transaction of $256,419.40. Following the sale, the executive vice president owned 138,043 shares of the company’s stock, valued at approximately $3,616,726.60. This represents a 6.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Floyd F. Petersen sold 2,426 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $25.92, for a total value of $62,881.92. Following the sale, the director owned 71,368 shares of the company’s stock, valued at approximately $1,849,858.56. The trade was a 3.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 13,950 shares of company stock worth $363,925. Insiders own 27.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AMPH. Farther Finance Advisors LLC grew its stake in Amphastar Pharmaceuticals by 356.0% during the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock worth $25,000 after purchasing an additional 737 shares during the period. FNY Investment Advisers LLC acquired a new position in Amphastar Pharmaceuticals in the third quarter valued at approximately $26,000. Global Retirement Partners LLC lifted its stake in Amphastar Pharmaceuticals by 219.0% in the third quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock valued at $27,000 after buying an additional 703 shares during the period. Quarry LP bought a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth approximately $32,000. Finally, Hantz Financial Services Inc. grew its position in shares of Amphastar Pharmaceuticals by 3,430.8% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock worth $32,000 after buying an additional 1,338 shares during the period. 65.09% of the stock is owned by institutional investors and hedge funds.

More Amphastar Pharmaceuticals News

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Management expects mid- to high-single-digit revenue growth for 2026 and is launching a new respiratory product, which provides a clear growth runway beyond the quarter that disappointed investors. Amphastar outlines mid- to high-single-digit revenue growth for 2026 while launching new respiratory product
• Positive Sentiment: Two sell-side shops lowered price targets from $34 to $30 but retained constructive ratings (Wells Fargo: overweight; Needham: buy), signaling that analysts still see significant upside from current levels despite trimming near-term assumptions. Analyst price target coverage
• Neutral Sentiment: Company published its Q4 press release, slide deck and conference call materials for investors to review detailed results and management commentary. These materials may clarify margin drivers and product cadence. Press release / slide deck
• Neutral Sentiment: Analyst and media write-ups (Zacks, Seeking Alpha, Investing.com) provide deeper metric-level analysis comparing results to estimates — useful for modeling but not new catalyst by itself. Zacks comparison of key metrics
• Negative Sentiment: Q4 results missed consensus: adjusted EPS of $0.73 vs. ~$0.97 expected and revenue of $183.1M vs. ~$190.5M, prompting investor concern about near-term growth and profit leverage. MarketBeat earnings summary
• Negative Sentiment: Market reaction has been amplified by heavy trading and coverage noting the miss; short-interest reports in public feeds are noisy/unclear but the immediate selloff reflects disappointment with the quarter. Yahoo finance: earnings miss and market reaction

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.